HIGHLIGHTS
- who: Alessio Rizzo and collaborators from the Department of Nuclear Medicine, Candiolo Cancer Institute, Turin, Italy University of Turin, Turin, Italy have published the research: PSMA Radioligand Uptake as a Biomarker of Neoangiogenesis in Solid Tumours: Diagnostic or Theragnostic Factor?, in the Journal: Cancers 2022, 4039 of /2022/
- what: The aim of this narrative review is to assess whether PSMA radioligands, employed as diagnostic or theragnostic factors, might play a role in the management of patients with solid tumours other than prostate cancer, with particular regard to the significance of PSMA radioligand uptake as a . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.